Beijing-based oncology-focused clinical data analysis systems developer LinkDoc Technology recently announced completion of RMB 1 bln in Series D funding in H1 2018. Participating in the round was sovereign wealth fund China Investment Corporation.
Zhang Tianze, CEO at LinkDoc, said that as of H1 2018 its medical big data platform covers approximately 60% of oncological disease types. As its data and technology resources have grown, the company has launched new AI-based diagnosis and treatment services and innovative pharmaceuticals industry services since early 2018. LinkDoc has also partnered with Tianjin Chest Hospital to develop the first lung cancer AI-based medical diagnosis support platform in the Tianjin-Beijing-Hebei area.
Editor's Note: LinkDoc was set up in December 2014, and mainly focuses on developing information systems for oncology specialists, helping clinics, for example, to establish EMR systems which allow doctors to check information relating to their patients' diagnoses and treatment. For more information on this topic, please see Oncology Clinical Data Anlaysis Systems Developer LinkDoc Completes Series B, MD 4/05/16 issue.